Curium Pharma

Are you a healthcare professional aiming to deepen your understanding of nuclear medicine and its applications across various diseases? With INVIVOX, you can access Curium's latest training session – a free 20-minute course providing an excellent introduction that will enhance your knowledge and skills. Participants will learn about: • How nuclear medicine works • The significance of nuclear medicine in various medical specialties • Nuclear medicine technologies • Advantages of nuclear medicine • Fundamental concepts, patient benefits, and clinical indications We invite you to join us and expand your knowledge in this critical field. Register now to secure your spot: https://lnkd.in/d9bs8s9B #NuclearMedicine #Healthcare #MedicalTraining

At Curium, we're working to reduce the impact we make on the world’s climate. As part of this dedication we spread awareness about climate change causes and consequences through Climate Fresk workshops organised for our teams.   Since September 2023, fourteen employees have been trained to deliver Climate Fresk workshops in multiple languages to Curium employees – bringing our teams together to explore and tackle the complexities of climate change.   We've already organized ten workshops worldwide, involving more than 100 employees. The enthusiasm and commitment of our teams to reducing our impact is truly inspiring!   With many more workshops in the pipeline, we're excited to continue empowering our employees with the knowledge to drive positive change for a sustainable future as we redefine the experience of cancer through our trusted legacy in nuclear medicine.  #ClimateAction #Sustainability #CuriumCares #ClimateFresk

For the past 30 years, we’ve been helping advance solutions in nuclear medicine for the neuroendocrine tumor (NET) community – dedicated to enhancing NET detection and diagnosis. https://lnkd.in/dQMzxX4X #30yearsinNETs #neuroendocrinetumors International Neuroendocrine Cancer Alliance Neuroendocrine Cancer Awareness Network Inc. LACNETS The Healing NET Foundation Cancer Advocacy Group of Louisiana (CAGLA)

Curium is excited to announce that we’ve submitted our 505(b)(2) New Drug Application for Lutetium Lu 177 Dotatate Injection to the FDA, which, if approved would be intended for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETS). This represents a notable step in Curium’s strategy to become a key player in the promising nuclear medicine therapeutic field.      Michael Patterson, CEO of Curium North America, states, “Curium’s 505(b)(2) new drug application for Lutetium Lu 177 Dotatate Injection marks another important milestone for Curium in its evolution to bring new tools for patients and healthcare providers to both diagnose and now potentially treat disease.  Nuclear medicine-based cancer therapies must continue to be more widely and reliably available for patients and their caregivers.” Curium is excited to embark on the next phase of its journey toward delivering cancer therapies to the market as part of its mission to redefine the experience of cancer through its trusted legacy in nuclear medicine.   https://lnkd.in/dAnJ2Q5R     #Curium #NuclearMedicine #CancerTherapies #InnovationInHealthcare #FDAApproval #GEPNETS #RadioligandTherapy #NETs #NeuroendocrineTumors

We recently hosted an employee webinar focused on the transformative power of integrative medicine and holistic care in cancer: sharing with employees how these approaches can significantly enhance the quality of life and positive health outcomes for individuals affected by cancer.   We were honored to have Joan Reventós, Director of the Fundación Kālida (part of the Maggie's Centres network) in Spain, and Francoise Vamecq, Co-founder and CEO of Oncia Community – who both shared their invaluable insights and experiences.   Curium is proud to partner with Oncia Community, a movement dedicated to reshaping cancer care. Oncia Community: https://lnkd.in/dxq-Zqw3 Kalida Foundation: https://lnkd.in/dgBgG59a #CancerCare #HolisticHealth #IntegrativeMedicine #EmployeeWebinar #PatientCentricCare

Curium is proud to have sponsored the RTNG Poster and Oral competition prizes at this year's British Nuclear Medicine Society exhibition. We are delighted to announce the winners who have demonstrated outstanding contributions to the field. 𝐑𝐓𝐍𝐆 𝐏𝐨𝐬𝐭𝐞𝐫 𝐏𝐫𝐢𝐳𝐞  - Awarded to: Carolina Rodrigues, Ana Moura, Amy Eccles, Vimal Gokani and Neil Soneji  - From: Imperial College Healthcare NHS Trust, London, United Kingdom  - Poster No. P008: "How to solve a problem: An unusual case for lymphoscintigraphy" 𝐑𝐓𝐍𝐆 𝐎𝐫𝐚𝐥 𝐏𝐫𝐢𝐳𝐞  - Awarded to: Sinéad Donnelly, Kathryn Adamson and Claire Jerrom - From: Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom  - Oral Presentation No. 37: "Inclusive Pregnancy - Improving the experience for gender non-conforming patients" Thank you to everyone who participated, and once again, congratulations to all the winners for their exceptional work and dedication! #BNMS2024 #Curium #NuclearMedicine #MedicalResearch 

Meet Hélène-Eve Bordier, our Europe Pharmacovigilance Manager at Curium! Reflecting on her role, Hélène shares, "The teamwork and preparation for pharmacovigilance inspections are truly memorable experiences." Curium fosters a collaborative environment across departments, particularly in pharmacovigilance, where we innovate alongside hospital researchers to pioneer targeted treatments for cancer and other diseases. Hélène advises future colleagues to embrace flexibility and curiosity, essential in our dynamic workplace. https://lnkd.in/dtfW5yZR   #Curium #EmployeeSpotlight #Innovation #NuclearMedicine #Healthcare #Teamwork #CareerGrowth

We are thrilled to announce the growing availability of PYLCLARI® across Europe! As of May 2024, PYLCLARI® is now available in Austria, marking a significant step in enhancing prostate cancer diagnostics. Benoit Woessmer, PET Europe CEO, stated, "Today's news that PYLCLARI® is now available to patients with prostate cancer in Austria is a testament to Curium's dedication and ambition for the country and healthcare professionals in Austria." In Austria alone, prostate cancer affects approximately 7,000 men annually. The availability of PYLCLARI®, produced at our Linz facility and administered at KABEG Klinikum Klagenfurt and a hospital in Linz, represents a significant advancement in the fight against this prevalent disease. Read full press release here: https://lnkd.in/dgUc8zkZ #ProstateCancer #PSMA #Pylclari

Did you miss Curium’s Seminar at European Association of Urology 2024 congress? Now you have the chance to catch up on all the groundbreaking discussions on-demand! Gain invaluable insights from distinguished speakers Prof. Dr. Jeroen van Moorselaar and Prof. Dr. Daniela Oprea-Lager as they navigate at the forefront of urological and nuclear medicine  advancements. "Nowadays PSMA PET/CT significantly improves the detection of prostate cancer," emphasized Prof. Dr. Jeroen van Moorselaar. Seize this exclusive opportunity to stay ahead of the latest developments in PSMA radiopharmaceuticals and PET imaging; elevate your knowledge and practice by registering today! https://lnkd.in/dnwTivgy   #EAU24 #radiopharmaceuticals #nuclearmedicine #molecularimaging #clinicaltrials #urology #prostatecancer #oncology  #MedicalImaging #PSMAImaging #EAU2024 #UrologyCongress

Meet Guillaume Garcia, Head of New Drug Application group at Curium. With a passion for radiochemistry and a commitment to patient care, Guillaume embodies Curium's values of innovation, dynamism, and excellence. "Curium's culture of innovation empowers us to make a real difference in patients' lives every day.” he says. For those considering a career at Curium, Guillaume offers valuable advice: stay curious, be dynamic, and embrace full engagement. Let's continue to shape healthcare together! https://lnkd.in/dG_PztiU   #Curium #EmployeeSpotlight #Innovation #NuclearMedicine #Healthcare #Teamwork #CareerGrowth